

FORM PTO-1595
1-31-92
(modified)

RECORDATION FORM COVER SHEET
PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE


I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313-1450, Patent and Trademark Assignment System, at (703) 306-5995, on
Date June 21, 2004
Signature Jonas Pierre, Sr.

To the Commissioner of Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): 1. KOSTENIS, Evi 3. HUBER, Jochen 5. BUELTMANN, Andreas 7. MUENCH, Gotz	2. WOHLFART, Paulus 4. ROSPORT, Kai 6. BAUMGARTNER, Christine 8. UNGERER, Martin	2. Name and address of receiving party(ies): Name: Aventis Pharma Deutschland GmbH Internal Address: Street Brüningstrasse 50 Address: City: Frankfurt am Main State: GERMANY ZIP: 65929
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO		Additional name(s) and address(es) attached? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
3. Nature of Conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Other Change the name spelling of the 4th inventor from "GOTZINGER, Kai Rosport" to "ROSPORT, Kai" Execution Date: 1.) 1/27/2004 2.) 1/19/2004 3.) 1/21/2004 4.) 1/27/2004 5.) 1/22/2004 6.) 1/21/2004 7.) 1/20/2004 8.) 1/20/2004		

4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No.(s): 10/706,763		B. Patent No.(s): Additional numbers attached? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
5. Name and address of party to whom correspondence concerning document should be mailed: Name: F. Aaron Dubberley, Reg. No. 41,001 Internal Address: Aventis Pharmaceuticals Inc. Street Address: Route 202-206 / P.O. Box 6800 City: Bridgewater State: NJ ZIP: 08807-0800 ** FAX NUMBER: (908) 231-2626 ** Our Reference No.: DEAV2002/0083 US NP		6. Total number of applications and patents involved: 1 7. Total (37 CFR 3.41): \$40.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account 8. Deposit account number: 18-1982

DO NOT USE THIS SPACE

9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. <u>F. Aaron Dubberley, Reg. No. 41,001</u> Name of Person Signing	 Signature Date: <u>June 21, 2004</u> Total number of pages comprising cover sheet: 13
---	--

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion
Mail documents to be recorded with required cover sheet information to:
Mail Stop Assignments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office Information Systems, PK2-1000C, Alexandria, VA 22313-1450, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Alexandria, VA 22304.

CH \$40.00 181982 10706763

FORM PTO-1595
1-31-92
(modified)

RECORDATION FORM COVER SHEET PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313-1450, Patent and Trademark Assignment System, at (703) 306-5995, on

Date March 2, 2004

Signature Jonas Pierre, Sr.

To the Commissioner of Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

1. KOSTENIS, Evi
3. HUBER, Jochen
5. BUELTSMANN, Andreas
7. MUENCH, Gotz

2. WOHLFART, Paulus
4. GOTZINGER, Kai Rosport
6. BAUMGARTNER, Christine
8. UNGERER, Martin

Additional name(s) of conveying party(ies) attached? ☐ YES ☒ NO

2. Name and address of receiving party(ies):

Name: **Aventis Pharma Deutschland GmbH**

Internal

Address:

Street **Brüningstrasse 50**

Address:

City: **Frankfurt am Main** State: **GERMANY** ZIP: **65929**

Additional name(s) and address(es) attached? ☐ YES ☒ NO

3. Nature of Conveyance:

☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Execution Date: 1.) 1/27/2004 2.) 1/19/2004 3.) 1/21/2004
4.) 1/27/2004 5.) 1/22/2004 6.) 1/21/2004
7.) 1/20/2004 8.) 1/20/2004

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s): **10/706,763**

B. Patent No.(s):

Additional numbers attached? ☐ YES ☒ NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **F. Aaron Dubberley, Reg. No. 41,001**
Internal Address: **Aventis Pharmaceuticals Inc.**
Street Address: **Route 202-206 / P.O. Box 6800**
City: **Bridgewater** State: **NJ** ZIP: **08807-0800**
**** FAX NUMBER: (908) 231-2626 ****
Our Reference No.: **DEAV2002/0083 US NP**

6. Total number of applications and patents involved: **1**

7. Total (37 CFR 3.41):..... **\$40.00**

☐ Enclosed

☒ Authorized to be charged to deposit account

8. Deposit account number: **18-1982**

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

F. Aaron Dubberley, Reg. No. 41,001

Name of Person Signing

F. Aaron Dubberley

Signature

Date: **March 2, 2004**

Total number of pages comprising cover sheet: **4**

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignments

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office Information Systems, PK2-1000C, Alexandria, VA 22304-4100, or to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Alexandria, VA 22304-3222.

PATENT

REEL: 014858 FRAME: 0607

DI ' 2002/0083 US NP

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Evi Kostenis, Langwiesenweg 29, 36323 Grebenau
- 2) Dr. Paulus Wohlfart, Bertolt-Brecht-Ring 16c, 64625 Bensheim
- 3) Dr. Jochen Huber, Speyererstrasse 3, 67133 Maxdorf
- 4) Kai Rosport, Gotzinger Strasse 44, 81371 München
- 5) Dr. Andreas Bueltmann, Claude-Lorrain-Strasse 35, 81543 München
- 6) Dr. Christine Baumgartner, Bavariastrasse 18 c, 80336 München
- 7) Dr. Götz Muench, Schellingstrasse 23, 80799 München
- 8) Dr. Martin Ungerer, Georgenstrasse 57, 80799 München

The Inventors are citizens of: 1) - 8) Germany

hereby sell, assign, and transfer unto **Aventis Pharma Deutschland GmbH**,
a corporation organized under the laws of Germany,
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of
the United States, executed concurrently herewith

Ser.-No.: **10/706,763**

filed: **November 12, 2003**

entitled: **Use of EDG2 receptor in an animal model of heart failure**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application
for Letters Patent, and in and to all divisional or continuation applications that may be filed for United
States Letters Patent for any of said inventions, and in and to all patents that may be granted on the
foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee,
its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal
proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent
protection on said inventions in the United States.

Inventor(s):

1st: *Evi Kostenis* Date: 27. 01. 2004

2nd: _____ Date: _____

3rd: _____ Date: _____

4th: _____ Date: _____

5th: _____ Date: _____

6th: _____ Date: _____

7th: _____ Date: _____

8th: _____ Date: _____

PATENT**REEL: 014858 FRAME: 0608**

D: 2002/0083 US NP

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Evi Kostenis, Langwiesenweg 29, 36323 Grebenau
- 2) Dr. Paulus Wohlfart, Bertolt-Brecht-Ring 16c, 64625 Bensheim
- 3) Dr. Jochen Huber, Speyererstrasse 3, 67133 Maxdorf
- 4) Kai Rosport, Gotzinger Strasse 44, 81371 München
- 5) Dr. Andreas Bueltmann, Claude-Lorrain-Strasse 35, 81543 München
- 6) Dr. Christine Baumgartner, Bavariastrasse 18 c, 80336 München
- 7) Dr. Götz Muench, Schellingstrasse 23, 80799 München
- 8) Dr. Martin Ungerer, Georgenstrasse 57, 80799 München

The inventors are citizens of: 1) - 8) Germany

hereby sell, assign, and transfer unto **Aventis Pharma Deutschland GmbH**,
a corporation organized under the laws of **Germany**,
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of
the United States, executed concurrently herewith

Ser.-No.: **10/706,763**

filed: **November 12, 2003**

entitled: **Use of EDG2 receptor in an animal model of heart failure**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application
for Letters Patent, and in and to all divisional or continuation applications that may be filed for United
States Letters Patent for any of said inventions, and in and to all patents that may be granted on the
foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee,
its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal
proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent
protection on said inventions in the United States.

Inventor(s):

1st: _____ Date: _____

2nd: Paulus Wohlfart Date: 19.1.2004

3rd: Jochen Huber Date: 27.1.2004

4th: _____ Date: _____

5th: _____ Date: _____

6th: _____ Date: _____

7th: _____ Date: _____

8th: _____ Date: _____

PATENT
REEL: 014858 FRAME: 0609

D. ' 2002/0083 US NP

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Evi Kostenis, Langwiesenweg 29, 36323 Grebenau
- 2) Dr. Paulus Wohlfart, Bertolt-Brecht-Ring 16c, 64625 Bensheim
- 3) Dr. Jochen Huber, Speyererstrasse 3, 67133 Maxdorf
- 4) Kai Rosport, Gotzinger Strasse 44, 81371 München
- 5) Dr. Andreas Bueltmann, Claude-Lorrain-Strasse 35, 81543 München
- 6) Dr. Christine Baumgartner, Bavariastrasse 18 c, 80336 München
- 7) Dr. Götz Muench, Schellingstrasse 23, 80799 München
- 8) Dr. Martin Ungerer, Georgenstrasse 57, 80799 München

The inventors are citizens of: 1) - 8) Germany

hereby sell, assign, and transfer unto **Aventis Pharma Deutschland GmbH**,
a corporation organized under the laws of Germany,
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of
the United States, executed concurrently herewith

Ser.-No.: **10/706,763**

filed: **November 12, 2003**

entitled: **Use of EDG2 receptor in an animal model of heart failure**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application
for Letters Patent, and in and to all divisional or continuation applications that may be filed for United
States Letters Patent for any of said inventions, and in and to all patents that may be granted on the
foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee,
its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal
proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent
protection on said inventions in the United States.

Inventor(s):

1st: _____ Date: _____

2nd: _____ Date: _____

3rd: _____ Date: _____

4th: Evi Kostenis Date: Jan 21, 2004

5th: Kai Rosport Date: Jan 22, 2004

6th: Christine Baumgartner Date: Jan 21, 2004

7th: Götz Muench Date: Jan 20, 2004

8th: Martin Ungerer Date: Jan 20, 2004

PATENT**REEL: 014858 FRAME: 0610**

DI 2002/0083 US NP

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Evi Kostenis, Langwiesenweg 29, 36323 Grebenau
- 2) Dr. Paulus Wohlfart, Bertolt-Brecht-Ring 16c, 64625 Bensheim
- 3) Dr. Jochen Huber, Speyererstrasse 3, 67133 Maxdorf
- 4) Kai Rosport, Gotzinger Strasse 44, 81371 München
- 5) Dr. Andreas Bueltmann, Claude-Lorrain-Strasse 35, 81543 München
- 6) Dr. Christine Baumgartner, Bavariastrasse 18 c, 80336 München
- 7) Dr. Götz Muench, Schellingstrasse 23, 80799 München
- 8) Dr. Martin Ungerer, Georgenstrasse 57, 80799 München

The inventors are citizens of: 1) - 8) Germany

hereby sell, assign, and transfer unto **Aventis Pharma Deutschland GmbH**,
a corporation organized under the laws of **Germany**,
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of
the United States, executed concurrently herewith

Ser.-No.: **10/706,763**

filed: **November 12, 2003**

entitled: **Use of EDG2 receptor in an animal model of heart failure**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application
for Letters Patent, and in and to all divisional or continuation applications that may be filed for United
States Letters Patent for any of said inventions, and in and to all patents that may be granted on the
foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee,
its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal
proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent
protection on said inventions in the United States.

Inventor(s):

1st: G. J. Ungerer Date: 27. 01. 2004

2nd: _____ Date: _____

3rd: _____ Date: _____

4th: _____ Date: _____

5th: _____ Date: _____

6th: _____ Date: _____

7th: _____ Date: _____

8th: _____ Date: _____

PATENT

REEL: 014858 FRAME: 0611

D: ' 2002/0083 US NP

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Evi Kostenis, Langwiesenweg 29, 36323 Grebenau
- 2) Dr. Paulus Wohlfart, Bertolt-Brecht-Ring 16a, 64625 Bensheim
- 3) Dr. Jochen Huber, Speyererstrasse 3, 67133 Maxdorf
- 4) Kai Rosport, Gotzinger Strasse 44, 81371 München
- 5) Dr. Andreas Bueltmann, Claude-Lorrain-Strasse 35, 81543 München
- 6) Dr. Christine Baumgartner, Bavariastrasse 18 c, 80336 München
- 7) Dr. Götz Muench, Schellingstrasse 23, 80799 München
- 8) Dr. Martin Ungerer, Georgenstrasse 57, 80799 München

The inventors are citizens of: 1) - 8) Germany

hereby sell, assign, and transfer unto **Aventis Pharma Deutschland GmbH**,
a corporation organized under the laws of **Germany**,
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of
the United States, executed concurrently herewith

Ser.-No.: **10/706,763**

filed: **November 12, 2003**

entitled: **Use of EDG2 receptor in an animal model of heart failure**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application
for Letters Patent, and in and to all divisional or continuation applications that may be filed for United
States Letters Patent for any of said inventions, and in and to all patents that may be granted on the
foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee,
its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal
proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent
protection on said inventions in the United States.

Inventor(s):

1st: _____ Date: _____

2nd: Paulus Wohlfart Date: 19.1.2004

3rd: Jochen Huber Date: 27.1.2004

4th: _____ Date: _____

5th: _____ Date: _____

6th: _____ Date: _____

7th: _____ Date: _____

8th: _____ Date: _____

PATENT**REEL: 014858 FRAME: 0612**

D. 2002/0083 US NP

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Evi Kostenis, Langwiesenweg 29, 36323 Grebenau
- 2) Dr. Paulus Wohlfart, Bertolt-Brecht-Ring 16c, 64625 Bensheim
- 3) Dr. Jochen Huber, Speyererstrasse 3, 67133 Maxdorf
- 4) Kai Rosport, Gotzinger Strasse 44, 81371 München
- 5) Dr. Andreas Bueltmann, Claude-Lorrain-Strasse 35, 81543 München
- 6) Dr. Christine Baumgartner, Bavariastrasse 18 c, 80336 München
- 7) Dr. Götz Muench, Schellingstrasse 23, 80799 München
- 8) Dr. Martin Ungerer, Georgenstrasse 57, 80799 München

The inventors are citizens of: 1) - 8) Germany

hereby sell, assign, and transfer unto **Aventis Pharma Deutschland GmbH**,
a corporation organized under the laws of **Germany**,
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of
the United States, executed concurrently herewith

Ser.-No.: **10/706,763**

filed: **November 12, 2003**

entitled: **Use of EDG2 receptor in an animal model of heart failure**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application
for Letters Patent, and in and to all divisional or continuation applications that may be filed for United
States Letters Patent for any of said inventions, and in and to all patents that may be granted on the
foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee,
its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal
proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent
protection on said inventions in the United States.

Inventor(s):

1st: _____ Date: _____

2nd: _____ Date: _____

3rd: _____ Date: _____

4th: Evi Kostenis Date: Jan 21, 2004

5th: Kai Rosport Date: Jan 22, 2004

6th: Christine Baumgartner Date: Jan 21, 2004

7th: Götz Muench Date: Jan 20, 2004

8th: Martin Ungerer Date: Jan 20, 2004

PATENT**RECORDED: 07/15/2004****REEL: 014858 FRAME: 0613**